r studio version 2.15.2 (RStudio)
90
Structured Review
RStudio
r studio version 2.15.2
R Studio Version 2.15.2, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/r+studio+version+2%2E15%2E2/r+studio+version+2+15+2/pm37229836-34-8-6
Average 90 stars, based on 1 article reviews
R Studio Version 2.15.2, supplied by RStudio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/r+studio+version+2%2E15%2E2/r+studio+version+2+15+2/pm37229836-34-8-6
Average 90 stars, based on 1 article reviews
r studio version 2.15.2 - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages. Article Snippet: All plots were generated using Numbers (iWORK’09) or Article Title: Juvenile Chinook salmon use of sandbar willows in a large-scale, simulated riparian floodplain: microhabitat and energetics Article Snippet: 1 3 Statistical analyses Data were analyzed using Article Title: Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer Article Snippet: All statistical analyses were performed with Article Title: Monosodium Urate Crystals Regulate a Unique JNK-Dependent Macrophage Metabolic and Inflammatory Response Article Snippet: All plots were generated using Numbers (iWORK Article Title: Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. Article Snippet: Introduction: Chemotherapy plus immunotherapy is the standard of care for patients with metastatic NSCLC.. No study has evaluated the outcomes of second-line chemotherapy treatments after progression following first-line chemo-immunotherapy.. Method: This multicenter retrospective study evaluated the efficacy of second line (2L) chemotherapies after progression under first-line (1L) chemo-immunotherapy, measured by overall survival (2L-OS) and progression free survival (2L-PFS). Article Title: Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort. Article Snippet: Julien Taïeb (MD-PhD) a,b,,1, Lina Sayah (MD) , Kathrin Heinrich (MD) , Volker Kunzmann (MD) , Alice Boileve (MD) , Geert Cirkel (MD) , Sara Lonardi (MD) , Benoist Chibaudel , Anthony Turpin (MD) , Tamar Beller (MD) , Vincent Hautefeuille (MD) , Caterina Vivaldi (MD) , Thibault Mazard (MD-PhD) , Lucile Bauguion (MD) , Monica Niger (MD) , Gerald W. Prager (MD) , Clelia Coutzac , C. Benedikt Westphalen (MD) , Edouard Auclin (MD) , Lorenzo Pilla (MD) a,1 Article Title: Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. Article Snippet: All statistical analyses were performed with |